Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma

NCT04845139 is registered in ClinicalTrials.gov with Second Affiliated Hospital, Zhejiang University, School of Medicine as lead sponsor.

NCT NCT04845139
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04845139 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase
Not applicable
Overall status
Unknown status
Start date
July 2, 2022
Completion date
November 30, 2022
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary central nervous system lymphoma, refractory central nervous system lymphoma, relapsed primary central nervous system lymphoma